Phase 2 N=336 Indocyanine Green for Central Nervous System Tumors
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
Phase 3 N=256 Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.90; 2.08; 3.64; 1.74 mean of a score (on a scale) per patient — p=<.0001
Phase 2 N=280 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Contrast to Noise Ratio (CNR) Difference — -10.59; 2.18; 8.66; 14.45 Ratio — p=0.1858
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
N/A N=40 Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
Chronic Pain
Primary: Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation — 32 Participants
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
N/A N=15 Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain
Pain · Low Back Pain · Leg Pain
Primary: Cerebral Blood Flow and VAS With Optimal Paresthesia Coverage Compared With SCS Off
N/A N=21 Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy
Hearing Loss
Primary: CNC Monosyllabic Word Score - Treated Ear — 57.1 percent correct
Phase 2 N=58 Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: UPDRS Part III OFF — -7.21; -6.91 units on a scale
N/A N=112 Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
Intractable Chronic Migraine
Primary: Adverse Events (First 12 Weeks) — 17; 27; 5; 1 events
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
N/A N=18 Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries
Spinal Cord Injury
Primary: Standing Performance — 27.4; 15.6 minutes
Phase 1 N=24 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
Healthy Volunteers
Primary: Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5…
Phase 4 N=4 Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CNS Sarcoidosis
Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants
N/A N=7 Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS
Multiple Sclerosis
Primary: Expanded Disability Status Score — 6.8 score on a scale
N/A N=12 Intraoperative Neuromonitoring Recording With a Novel SCS Paddle
Chronic Pain · Neuropathic Pain · Failed Back Surgery Syndrome
Primary: Numeric Rating Scale (NRS) — 5.333333333 score on a scale
Phase 3 N=240 RNS® System Pivotal Study
Epilepsy
Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE
Phase 4 N=20 Temperature Control in Central Fever in the Neuro-ICU
Fever · Brain Hemorrhage
Primary: Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care — 100.8; 100.3; 99.9; 99.5 degrees F
N/A N=127 Deep Brain Stimulation (DBS) for the Suppression of Tremor
Tremor · Action Tremor · Essential Tremor
Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer…
Phase 3 N=402 Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
Diagnostic Self Evaluation · Central Nervous System Diseases
Primary: MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation — 1.06; 3.30; 1.62…
N/A N=6 Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Trunk Impairment Scale (TIS) — 0.82; 2.58; 1.47; 1.63 percentage of change
N/A N=42 Electrically Evoked Compound Action Potentials Human Observation Medtronic Algorithm Comparison Study
Chronic Pain
Primary: The Proportion of Subjects With a Reduction in Overstimulation Sensation With SCS Using a Closed-loop Algorithm Compared With SCS in Open-loop — 41 Participants — p=<0.001